Immunodeficiency Clinical Trial
Official title:
Expanded Access Protocol Thymus Transplantation for Immunodeficiency, Hematologic Malignancies, and Autoimmune Disease Related to Poor Thymic Function
The primary purpose is to provide access for patients who have immunodeficiency or severe autoimmune disease related to poor thymic function to cultured thymus tissue for implantation. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection. Eligible participants receive cultured thymus tissue for implantation and may undergo biopsy. Immune suppression may be given depending on the immune status and clinical condition of the participant. Immune function testing is continued for one year post-implantation.
The patients enrolled have a high likelihood of death if they do not receive culture thymus tissue because of lack of thymus function. As there are many types of patients who may be enrolled, study results will not have statistical significance. The study objective is to make cultured thymus tissue available for implantation on an expanded access basis. Data will be collected on survival, naïve T cell development, T cell chimerism, and implant related toxicities, as well as any unexpected study-related serious adverse events. Eligible subjects receive cultured thymus tissue and may undergo allograft biopsy. Immune suppression may be given depending on the subject's immune status and clinical condition. Protocol specified studies continue until approximately one year post-implantation. Study participation lasts approximately two years. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02345135 -
Susceptibility to Infections in Ataxia Telangiectasia
|
N/A | |
Completed |
NCT04553705 -
Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)
|
Phase 2/Phase 3 | |
Completed |
NCT00758992 -
Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages
|
N/A | |
Recruiting |
NCT05907746 -
Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency
|
Phase 2 | |
Active, not recruiting |
NCT02291965 -
Blood Samples to Identify Biomarkers of Busulfan
|
||
Recruiting |
NCT04408950 -
Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects
|
||
Completed |
NCT00923364 -
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
|
Phase 2 | |
Withdrawn |
NCT05672654 -
Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients
|
N/A | |
Recruiting |
NCT05405491 -
Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation
|
N/A | |
Recruiting |
NCT01800643 -
Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation
|
Phase 2/Phase 3 | |
Recruiting |
NCT00001467 -
Genetic Analysis of Immune Disorders
|
||
Not yet recruiting |
NCT04447937 -
Immunodeficiency in MS
|
||
Completed |
NCT00925925 -
Epigenetic Markers of B-Cell Function in Low Birth Weight Infants
|
N/A | |
Recruiting |
NCT01861106 -
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
|
Phase 2 | |
Recruiting |
NCT06248957 -
SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION
|
||
Suspended |
NCT05027945 -
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05655546 -
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
|
N/A | |
Completed |
NCT03374566 -
Immunodeficiency for Severe Epstein-Barr Virus Infection
|
||
Terminated |
NCT01027702 -
Donor Lymphocyte Infusion After Alternative Donor Transplantation
|
Phase 1/Phase 2 |